Polaryx Therapeutics, Inc. (PLYX)

Market Cap	289.74M
Revenue (ttm)	n/a
Net Income	-8.99M
EPS	-0.20
Shares Out	47.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,236
Open	6.43
Previous Close	6.39
Day's Range	5.91 - 6.93
52-Week Range	2.20 - 48.91
Beta	n/a
Analysts	Strong Buy
Price Target	10.00 (+63.4%)
Earnings Date	May 14, 2026

About PLYX

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was found...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: PLYX
• Website: https://polaryx.com

Analyst Summary

According to one analyst, the rating for PLYX stock is "Strong Buy" and the 12-month stock price target is $10.0.

Price Target

$10.0

(63.40% upside)

Analyst Consensus: Strong Buy